Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion

Yoon Mi Shin; Jieun Yun; Ok-Jun Lee; Hye-Suk Han; Sung-Nam Lim; Jin Young An; Ki Hyeong Lee; Ki Man Lee; Kang Hyeon Choe

doi:10.4143/crt.2014.46.2.178

Articles

Page Path: HOME > Cancer Res Treat > Volume 46(2); 2014 > Article

Original Article Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion: Yoon Mi Shin, MD¹, Jieun Yun, PhD², Ok-Jun Lee, MD³, Hye-Suk Han, MD, PhD⁴, Sung-Nam Lim, MD⁴, Jin Young An, MD⁴, Ki Hyeong Lee, MD⁴, Ki Man Lee, MD⁴, Kang Hyeon Choe, MD⁴; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2014;46(2):178-185.
DOI: https://doi.org/10.4143/crt.2014.46.2.178
Published online: April 15, 2014

¹Department of Internal Medicine, Cheongju St. Mary Hospital, Cheongju, Korea.

²Bioevaluation Center, Korea Research Institute of Bioscience and Biotechnology, Cheongwon, Korea.

³Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea.

⁴Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.

Correspondence: Hye-Suk Han, MD, PhD. Department of Internal Medicine, Chungbuk National University College of Medicine, 776 1sunhwan-ro, Heungdeok-gu, Cheongju 361-711, Korea.
Tel: 82-43-269-6306, Fax: 82-43-273-3252, sook3529@hanmail.net

• Received: June 5, 2013 • Accepted: July 9, 2013

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

16,015 Views
136 Download
38 Web of Science
27 Crossref
41 Scopus

prev next

Full Article

Download PDF

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
Acknowledgments
NOTES
REFERENCES

Abstract

Purpose
The accurate and timely diagnosis of malignant pleural effusion (MPE) in lung cancer patients is important because MPE has a poor prognosis and is classified as stage IV disease. Molecular biomarkers for pleural effusion, such as circulating extracellular microRNAs (miRNAs) isolated from pleural fluid, may help in the diagnosis of MPE. The present study examined whether miRNAs that are deregulated in lung cancer (miR-134, miR-185, and miR-22) can serve as diagnostic markers for lung adenocarcinoma-associated MPE (LA-MPE).
Materials and Methods
Real-time reverse transcription quantitative polymerase chain reaction was used to measure the expression of the three miRNAs in samples from 87 patients with pleural effusion comprising 45 LA-MPEs and 42 benign pleural effusions (BPEs). The area under the receiver operating characteristic curve (AUC) was then used to evaluate the diagnostic performance of each of the three miRNAs and compare it with that of the common tumor marker, carcinoembryonic antigen (CEA).
Results
The expression of all three miRNAs was significantly lower in LA-MPE than in BPE (p <0.001). The AUCs for miR-134, miR-185, miR-22, and CEA were 0.721, 0.882, 0.832, and 0.898, respectively. Combining CEA with the three miRNAs increased the diagnostic performance, yielding an AUC of 0.942 (95% confidence interval, 0.864 to 0.982), with a sensitivity of 91.9% and a specificity of 92.5%.
Conclusion
The present study suggests that the expression levels of circulating extracellular miR-134, miR-185, and miR-22 in patients with pleural effusion may have diagnostic value when differentiating between LA-MPE and BPE.
Key words: Adenocarcinoma, Lung, miR-134, miR-185, miR-22, Pleural effusion

Introduction

Approximately 15% of lung cancer patients present with a pleural effusion at the time of initial diagnosis, and 50% develop a pleural effusion later in their disease course [1,2]. Pleural effusions can occur in patients with lung carcinomas of all histological types; however, they are more common in those with adenocarcinoma (40% of all pleural effusion cases) [2]. Metastatic malignant pleural effusion (MPE) due to lung cancer has a poor prognosis; MPE has been reclassified as M1a disease because its outcome is equivalent to that of distant metastasis [3]. Therefore, a diagnosis of MPE is important for lung cancer patients. Lung cancer patients suspected of having a pleural effusion undergo a chest X-ray and contrast-enhanced computed tomography to confirm the presence of fluid in the pleural cavity and to evaluate the pleura for nodularity or thickening, which may suggest metastasis [4]. Image-guided aspiration of the pleural fluid is often performed; however, the diagnosis of MPE by pleural fluid cytology has a sensitivity of only 60% with repeated large-volume (>50 mL) thoracentesis [5]. Therefore, it would be useful to identify biomarkers in the pleural fluid that can be used to improve diagnostic sensitivity. A systemic review found that carcinoembryonic antigen (CEA) showed good specificity (94%) but poor sensitivity (54%) for the diagnosis of MPE [6]. In addition, several studies examined different combinations of biomarkers in an attempt to improve diagnostic accuracy. Thus, there is a need to identify alternative noninvasive diagnostic biomarkers to improve the diagnosis of pleural effusions.

MicroRNAs (miRNAs) are a family of endogenous small (approximately 22 nucleotides in length) non-coding and functional RNAs that regulate the expression of many genes [7]. Aberrant expression of miRNAs occurs in many types of cancer, and several miRNAs function as tumor suppressor genes or oncogenes [8]. Recently, circulating extracellular miRNAs (in serum, plasma, pleural fluid, ascites, and other body fluids) were identified as noninvasive biomarkers for the diagnosis, prognosis, and prediction of responses to cancer treatment [9,10]. The present study examined the expression levels of three circulating miRNAs (miR-134, miR-185, and miR-22) in pleural effusion fluid; these miRNAs are deregulated in lung cancer. miR-134 regulates cell proliferation, apoptosis, and migration, and inhibits epithelial to mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) [11,12]; miR-185 suppresses the proliferation in lung adenocarcinoma cell lines and induces cell cycle arrest at the G1 phase [13]; miR-22 inhibits the growth and invasion of lung cancer by downregulating the expression of ErbB3 [14]. Given the diagnostic and prognostic potential of miR-134, miR-185, and miR-22 in lung cancer, we investigated the diagnostic significance of these miRNAs in patients with benign pleural effusion (BPE) and lung adenocarcinoma-associated MPE (LA-MPE) and compared it with that of the most commonly used tumor marker, CEA.

Materials and Methods

1. Patients and pleural fluid collection

We analyzed pleural fluid samples from 87 patients with pleural effusion who visited Chungbuk National University Hospital and Kangwon National University Hospital between February 2009 and April 2012. Pleural effusion was diagnosed as benign based on the clinical context and the absence of malignant cells in at least two separate samples from the same patient. BPE samples were obtained from patients showing no clinical or radiological evidence of malignancy prior to the study. LA-MPE was confirmed by pathological diagnosis based on the presence of adenocarcinoma cells. LA-MPE samples were obtained from patients showing no evidence of another malignant tumor and either 1) positive immunocytochemical staining for thyroid transcription factor-1 in MPE cell blocks, or 2) tumors that were histologically and/or clinically diagnosed as primary adenocarcinomas of the lung.

All effusion samples were collected before the start of cancer-directed therapy and were transported to the laboratory within 30 minutes of collection. The samples were then centrifuged at 11,300 ×g for 5 minutes. The supernatant and sediment from each sample were aliquoted into separate Eppendorf tubes and stored at -80℃ until use. All patients provided written informed consent to participate in the study, which was reviewed and approved by the Institutional Review Board of Chungbuk National University Hospital.

2. RNA extraction and real-time reverse transcription quantitative polymerase chain reaction

RNA was extracted from each sample (500 µL of sample) using a urine miRNA purification kit (Genolution Pharmaceuticals Inc., Seoul, Korea) according to the manufacturer's instructions. The amount of RNA extracted from each sample was measured using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE).

The expression levels of miR-134, miR-185, and miR-22 in 42 BPE samples and 45 LA-MPE samples were measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR). Isolated miRNA (100 ng) was reverse transcribed using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol and using a specific miRNA primer that was provided with the TaqMan MicroRNA Assay kit (Applied Biosystems). Quantification of miRNA was performed by real-time RT-qPCR using an Applied Biosystems 7500 Fast Real-Time PCR System along with the TaqMan MicroRNA Assay, TaqMan Universal PCR Master Mix, and No AmpErase UNG (Applied Biosystems). All reactions were run in triplicate and Cq data were determined using default threshold settings. Relative miRNA expression levels were calculated using the 2^-ΔΔCt method. The selection of suitable genes for the relative quantification of miRNA expression is essential to avoid inaccurate results and to improve the comparability of gene expression data. We previously examined the expression of the selected miRNAs, two small nuclear RNAs (RNU6B and U6 snRNA), and two small nucleolar RNAs (RNU44 and RNU48) to identify the most stably expressed genes for use as reference genes in pleural effusion samples [15]. U6 snRNA was identified as the most stable reference gene in the BPE and LA-MPE samples; thus, the expression levels of the three miRNAs were normalized to those of U6 snRNA.

3. Immunoassay for CEA

After performing the miRNA analyses, additional immunoassays were conducted to measure the levels of CEA expression in patients with pleural effusion. CEA levels were measured in an electrochemiluminescence immunoassay using a Cobas 8000 e602 analyzer (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions.

4. Statistical analysis

Differences in miR-134, miR-185, miR-22, and CEA expression between LA-MPE and BPE samples were assessed using the Mann-Whitney U test. A receiver operating characteristic (ROC) curve was plotted and the area under the curve (AUC) was calculated to evaluate the diagnostic performance of the three miRNAs and CEA. The best sensitivity/specificity pair was selected (with a specificity of least 0.6). Risk scores were assigned to all patients according to a linear combination of the expression level of the miRNAs and CEA, weighted according to the regression coefficient. Cox stepwise regression and stratification analyses were also conducted. All statistical analyses were performed using SPSS ver. 15.0 (SPSS Inc., Chicago, IL). The MedCalc ver. 10.4.7.0 (MedCalc, Mariakerke, Belgium) software was used to perform the ROC analysis. All p-values were two-sided and p<0.05 was considered statistically significant.

Results

1. Patient characteristics

Eighty-seven pleural effusion samples (42 BPE and 45 LA-MPE) were analyzed by RT-qPCR. Table 1 shows the baseline characteristics of the patients in the BPE and LA-MPE groups. The median age of the BPE patients was 61 years (range, 22 to 92 years) and that of the LA-MPE patients was 68 years (range, 33 to 92 years). The majority of BPE patients were diagnosed with tuberculous pleurisy or parapneumonic effusion. Twenty-seven patients with LA-MPE had stage M1b disease at presentation.

2. Expression levels of miR-134, miR-185, miR-22, and CEA in BPE and LA-MPE

The expression levels of miR-134, miR-185, and miR-22 in LA-MPE samples were significantly lower than in BPE samples (all p<0.001, Mann-Whitney U test) (Fig. 1A-C). The median expression levels of miR-134, miR-185, and miR-22 were 19.758 (range, 0.069 to 243.601), 1.229 (range, 0.015 to 47.948), and 1.074 (range, 0.001 to 95.377), respectively, in BPE samples and 4.209 (range, 0.005 to 143.520), 0.008 (range, 0.000 to 2.852), and 0.008 (range, 0.000 to 8.562), respectively, in LA-MPE samples.

Of the 87 effusion samples, 77 were available for CEA testing. The median CEA expression level was significantly higher in the LA-MPE samples than in the BPE samples (127 ng/mL; range, 0.2 to 6,574 ng/mL vs. 1.0 ng/mL; range, 0.2 to 33.3 ng/mL) (p<0.001) (Fig. 1D).

3. Diagnostic performance of miR-134, miR-185, miR-22, and CEA for LA-MPE

The diagnostic performance of miR-134, miR-185, miR-22, and CEA (and a combination of these markers) in differentiating BPE from LA-MPE was evaluated by ROC curve analysis (Table 2). Cut-off points were determined such that they maximized the sum of sensitivity and specificity. The cut-off points for miR-134, miR-185, miR-22, and CEA were 16.99, 0.092, 0.051, and 7.6 ng/mL, respectively. The diagnostic accuracy of miR-134, miR-185, and miR-22, as measured by the AUC, was 0.721, 0.882, and 0.832, respectively (Fig. 2A-C). The AUC for CEA was 0.898, with a sensitivity of 78.4% and a specificity of 97.5% (Fig. 2D). The predicted probability of being diagnosed with LA-MPE from the logit model based on the three miRNAs [logit=(-0.020×expression level of miR-134)+(-1.103×expression level of miR-185)+(-0.452×expression level of miR-22)] was used to construct a ROC curve. The AUC for the combined miRNAs was 0.893 (95% confidence interval [CI], 0.808 to 0.949), with a sensitivity of 73.3% and a specificity of 97.6% (Fig. 2E). The predicted probability of being diagnosed with LA-MPE from the logit model based on a combination of the three miRNAs plus CEA [logit=(-0.017×expression level of miR-134)+(-1.148×expression level of miR-185)+(0.332×expression level of miR-22)+(0.127×expression level of CEA)] was also used to construct a ROC curve. The AUC for a combination of all four markers was 0.942 (95% CI, 0.864 to 0.982), with a sensitivity of 91.9% and a specificity of 92.5% (Fig. 2F).

Discussion

The present study demonstrated that LA-MPE samples showed significantly lower expression of miR-134, miR-185, and miR-22 than BPE samples. This suggests that all three miRNAs may be useful diagnostic biomarkers for differentiating between BPE and LA-MPE. In addition, the diagnostic performance of the three combined miRNAs (AUC, 0.893) was comparable with that of CEA (AUC, 0.898). CEA is a useful diagnostic biomarker for patients with pleural effusion; however, CEA is found to confer good specificity but relatively poor sensitivity for the diagnosis of LA-MPE [6]. The combination panel comprising miR-134, miR-185, miR-22, and CEA improved the diagnostic value (AUC, 0.942); in particular, the sensitivity increased to 91.9%.

Research on the prevention and early diagnosis of cancer has focused on identifying biomarkers that can help to detect tumors using noninvasive diagnostic methods. Recently studies suggest that the profile of circulating miRNAs, as well as tissue miRNAs, could be used as a diagnostic biomarker for cancer [9,10]. miRNAs are found in all body fluids and show distinct compositions in different fluid types [10]. The stability of miRNAs in body fluids may be explained, at least in part, by the finding that they are present in extracellular vesicular structures, called exosomes, which protect them from degradation [10]. miRNA-containing exosomes are found not only in blood, but also in other types of body fluid. Circulating exosomes and tumor cells from patients with lung adenocarcinoma harbor similar miRNA signatures, and there appears to be a significant difference in exosomal miRNA levels between cancer patients and controls [16]. Therefore, it is possible that pleural fluid obtained from patients that are difficult to diagnose using clinical and radiological evaluation could also be assessed for the presence of these molecular biomarkers. Recently, Xie et al. [17] studied the expression levels of 22 miRNAs that were aberrantly expressed in the serum of lung cancer patients (82 patients with MPE and 28 patients with BPE). They reported that MPE showed higher expression levels of cell-free miR-24 and miR-30d than BPE. However, they included pleural effusion samples from heterogenous lung cancer patients and also examined ascites from gastric cancer patients.

In a previous study, we examined the differential expression of circulating miRNAs in BPE and LA-MPE samples using a peptide nucleic acid-based microarray [15]. The miRNA expression signatures were confirmed by RT-qPCR and cross-validated using an independent sample set. The results showed that the expression level of miR-198 was significantly lower in LA-MPE than in BPE. For the present study, we selected only three miRNAs (miR-134, miR-185, and miR-22) that are deregulated in lung cancer and examined their expression in plural effusion samples obtained from patients with BPE and LA-MPE by RT-qPCR. We found that the expression of miR-134, miR-185, and miR-22, was lower in LA-MPE than in BPE. Downregulation of certain miRNAs in cancer suggests that these miRNAs may have tumor suppressor characteristics. These three miRNAs are also reported to function as tumor suppressors in various cancers. The expression of miR-134 correlates with the invasive potential and EMT phenotype of NSCLC cells [11,12]. Functional assays showed that miR-134 inhibits EMT in NSCLC cells, and Forkhead box protein M1 (FOXM1), a potential metastasis promoter, was a direct and functional target of miR-134 [12]. Also, low expression of cell-free miR-134 in MPE is associated with poor survival in NSCLC patients [18]. miR-185 suppresses cell proliferation and induces G1 arrest in lung cancer cell lines [13]. The extent of the growth suppression induced by these miRNAs is similar to that induced by the tumor suppressor miRNA, let-7 [19]. However, miR-185 has a stronger effect on cell cycle progression than let-7. In contrast to its tumor suppressor role, miR-185 plays an oncogenic role in both renal cell carcinoma and colorectal cancers [20,21]. The implied involvement of miR-22 in the p53 tumor suppressor network suggests that it is a strong candidate tumor suppressor gene in human colon and liver cancers [22,23]. Moreover, miR-22 restores the cellular senescence program in cancer cells and acts as a tumor suppressor [24]. It also shows anti-lung cancer activity both in vitro and in vivo, possibly via the post-transcriptional regulation of ErbB3 [14]. However, miR-22 is also oncogenic in transformed human bronchial epithelial cells induced by anti-benzo[a]pyrene-7,8-diol-9,10-epoxide [25]. These discordant findings suggest that miRNAs may target different genes in different cell types, thereby contributing to distinct biological processes.

The present study has some limitations. First, patients with BPE as the control group were not matched with the LA-MPE patients with respect to age and gender, which may have affected the results. The second limitation of the study was that all of three miRNAs expression were downregulated in LA-MPE compared with BPE, and the cut-off points for miR-185 and miR-22 were very low. Therefore, the diagnostic performance of these miRNAs that have tumor suppressor characteristics could be worse than that of oncogenic miRNAs.

Conclusion

The present study showed that the circulating extracellular miR-134, miR-185, and miR-22 levels in pleural effusions can be used to differentiate between LA-MPE and BPE. Furthermore, a panel comprising all three miRNAs showed a diagnostic performance comparable with that of CEA. The combination of all three miRNAs plus CEA showed considerable clinical value for diagnosing LA-MPE, with much better sensitivity than CEA alone. Thus, we propose that miR-134, miR-185, and miR-22 could be used to develop a minimally invasive screening tool for the diagnostic evaluation of pleural effusions.

Acknowledgements

Acknowledgments

This research was supported by a Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science, and Technology (2007-0054930).

All effusion samples were provided by Chungbuk National University Hospital and Kangwon National University Hospital, members of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare, and Family Affairs. All samples derived from the National Biobank of Korea were obtained with patient informed consent using institutional review board-approved protocols. We appreciate the experimental assistance of the cancer research team at the Bioevaluation Center (Korea Research Institute of Bioscience and Biotechnology, Republic of Korea).

NOTES

Conflict of interest relevant to this article was not reported.

REFERENCES

1. Memon A, Zawadzki ZA. Malignant effusions: diagnostic evaluation and therapeutic strategy. Curr Probl Cancer. 1981;5:1–30. PMID: 6263549Article
2. Johnston WW. The malignant pleural effusion: a review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985;56:905–909. PMID: 4016683Article PubMed
3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–714. PMID: 17762336Article PubMed
4. See KC, Lee P. Advances in the diagnosis of pleural disease in lung cancer. Ther Adv Respir Dis. 2011;5:409–418. PMID: 21697244Article PubMed
5. Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991;4:320–324. PMID: 2068057PubMed
6. Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal. 2007;21:398–405. PMID: 18022924Article PubMed PMC
7. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009;55:623–631. PMID: 19246618Article PubMed
8. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–1281. PMID: 20026422Article PubMed
9. Zhou L, Zhao YP, Liu WJ, Dong J, Chen WY, Zhang TP, et al. Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev Anticancer Ther. 2012;12:283–288. PMID: 22316375Article PubMed
10. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids: the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467–477. PMID: 21647195Article PubMed PMC
11. Zhang X, Wang H, Zhang S, Song J, Zhang Y, Wei X, et al. MiR-134 functions as a regulator of cell proliferation, apoptosis, and migration involving lung septation. In Vitro Cell Dev Biol Anim. 2012;48:131–136. PMID: 22259016Article PubMed
12. Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y, et al. miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett. 2012;586:3761–3765. PMID: 23010597Article PubMed
13. Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One. 2009;4:e6677PMID: 19688090Article PubMed PMC
14. Ling B, Wang GX, Long G, Qiu JH, Hu ZL. Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol. 2012;138:1355–1361. PMID: 22484852Article PubMed
15. Han HS, Yun J, Lim SN, Han JH, Lee KH, Kim ST, et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer. 2013;133:645–652. PMID: 23354517Article PubMed
16. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009;10:42–46. PMID: 19289371Article PubMed
17. Xie L, Wang T, Yu S, Chen X, Wang L, Qian X, et al. Cell-free miR-24 and miR-30d, potential diagnostic biomarkers in malignant effusions. Clin Biochem. 2011;44:216–220. PMID: 21093424Article PubMed
18. Wang T, Lv M, Shen S, Zhou S, Wang P, Chen Y, et al. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS One. 2012;7:e43268PMID: 22937028Article PubMed PMC
19. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007;67:7713–7722. PMID: 17699775Article PubMed
20. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol. 2010;4:51PMID: 20420713Article PubMed PMC
21. Akcakaya P, Ekelund S, Kolosenko I, Caramuta S, Ozata DM, Xie H, et al. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol. 2011;39:311–318. PMID: 21573504Article PubMed
22. Yamakuchi M, Yagi S, Ito T, Lowenstein CJ. MicroRNA-22 regulates hypoxia signaling in colon cancer cells. PLoS One. 2011;6:e20291PMID: 21629773Article PubMed PMC
23. Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 2010;103:1215–1220. PMID: 20842113Article PubMed PMC
24. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, et al. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol. 2011;193:409–424. PMID: 21502362Article PubMed PMC
25. Liu L, Jiang Y, Zhang H, Greenlee AR, Yu R, Yang Q. miR-22 functions as a micro-oncogene in transformed human bronchial epithelial cells induced by anti-benzo[a]pyrene-7, 8-diol-9,10-epoxide. Toxicol In Vitro. 2010;24:1168–1175. PMID: 20170724Article PubMed

Fig. 1

Comparison of miR-134 (A), miR-185 (B), miR-22 (C), and carcinoembryonic antigen (CEA) (D) expression levels in benign pleural effusion (BPE) and lung adenocarcinoma-associated malignant pleural effusion (LA-MPE) samples. Statistical significance was determined by the Mann-Whitney U test.

Fig. 2

Receiver operating characteristic (ROC) curve analysis. The ROC plots for miR-134 (A), miR-185 (B), miR-22 (C), carcinoembryonic antigen (CEA) (D), a combination of three miRNAs (E), and a combination of three miRNAs plus CEA (F) were used to differentiate lung adenocarcinoma-associated malignant pleural effusion from benign pleural effusion. AUC, area under the receiver operating characteristic curve; CI, confidence interval.

Table 1

Characteristics of the study populations

	No. of patients (n=87)

	BPE	LA-MPE
No. of cases	42	45
Median age (range, yr)	61 (22-92)	68 (33-92)
Gender
Male	29	23
Female	13	22
Diagnosis of BPE
Tuberculosis	20
Pneumonia	17
Transudate	5
Metastatic sites of LA
M1a^a)		18
M1b^b)		27

BPE, benign pleural effusion; LA-MPE, lung adenocarcinoma-associated malignant pleural effusion; LA, lung adenocarcinoma.

^a) M1a, separate tumor nodule(s) in a contralateral lobe, a tumor with pleural nodules, or malignant pleural (or pericardial) effusion,

^b) M1b, distant metastasis.

Table 2

Sensitivity, specificity, and areas under the curves for miR-134, miR-185, miR-22, CEA, and combinations of these markers, in lung adenocarcinoma-associated malignant pleural effusion samples

Tumor marker	Cut-off	Sensitivity (%)	Specificity (%)	AUC (95% CI)
miR-134	16.99	80.0	57.1	0.721 (0.614-0.812)
miR-185	0.092	77.8	90.5	0.882 (0.795-0.941)
miR-22	0.051	68.9	85.7	0.832 (0.736-0.903)
CEA	7.6	78.4	97.5	0.898 (0.808-0.955)
miR-134, miR-185, and miR-22	0.490	73.3	97.6	0.893 (0.808-0.949)
miR-134, miR-185, miR-22, and CEA	0.268	91.9	92.5	0.942 (0.864-0.982)

CEA, carcinoembryonic antigen; AUC, area under the curve; CI, confidence interval.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Key methodological challenges in detecting circulating miRNAs in different biofluids
Chitra Mestry, Tester F Ashavaid, Swarup AV Shah
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2023; 60(1): 14. CrossRef
MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy
Yongan Song, Leonardo Kelava, István Kiss
International Journal of Molecular Sciences.2023; 24(17): 13302. CrossRef
High Diagnostic and Prognostic Value of miRNAs Compared with the Carcinoembryonic Antigen As A Traditional Tumor Marker
Neda Yaghoubi , Farnaz Zahedi Avval , Majid Khazaei, Amirhossein Sahebkar , Seyed Hamid Aghaee-Bakhtiari
Anti-Cancer Agents in Medicinal Chemistry.2022; 22(2): 206. CrossRef
Diagnostic utility of pleural cell-free nucleic acids in undiagnosed pleural effusions
Wen Zhao, Xi-Shan Cao, Yu-Ling Han, Xu-Hui Wen, Wen-Qi Zheng, Zhi-De Hu
Clinical Chemistry and Laboratory Medicine (CCLM).2022; 60(10): 1518. CrossRef
Construction and analysis of expression profile of exosomal lncRNAs in pleural effusion in lung adenocarcinoma
Xiaolu Huang, Huixin Zhou, Xiang Yang, Wenjing Shi, Lijuan Hu, Junjun Wang, Fan Zhang, Fanggui Shao, Meijuan Zhang, Feng Jiang, Yumin Wang
Journal of Clinical Laboratory Analysis.2022;[Epub] CrossRef
Molecular testing on serous effusions
Ben Davidson
Diagnostic Cytopathology.2021; 49(5): 640. CrossRef
Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
Cancers.2021; 13(11): 2798. CrossRef
Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non‑small cell lung cancer
He-Guo Jiang, Chun-Hua Dai, Ya-Ping Xu, Qian Jiang, Xian-Bin Xia, Yang Shu, Jian Li
Oncology Letters.2021;[Epub] CrossRef
Molecular testing on serous effusion: An update
Saumya Sahu, Parikshaa Gupta, Pranab Dey
Cytojournal.2021; 18: 35. CrossRef
Non-coding RNA and lung cancer progression
Afeez Adekunle Ishola, Anita Silas La’ah, Hung Dinh Le, Viet Quoc Nguyen, Yi-Ping Yang, Shih-Jie Chou, Hsiao-Yun Tai, Chian-Shiu Chien, Mong-Lien Wang
Journal of the Chinese Medical Association.2020; 83(1): 8. CrossRef
Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview
Cristina Elena Staicu, Dragoș-Valentin Predescu, Călin Mircea Rusu, Beatrice Mihaela Radu, Dragos Cretoiu, Nicolae Suciu, Sanda Maria Crețoiu, Silviu-Cristian Voinea
Cells.2020; 9(1): 169. CrossRef
microRNA exchange via extracellular vesicles in cancer
Luyen Tien Vu, Jinhua Gong, Thach Tuan Pham, Yeokyeong Kim, Minh T. N. Le
Cell Proliferation.2020;[Epub] CrossRef
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
Kimberly A. Birnie, Cecilia M. Prêle, Arthur W. (Bill) Musk, Nicholas de Klerk, Y. C. Gary Lee, Deirdre Fitzgerald, Richard J. N. Allcock, Philip J. Thompson, Jenette Creaney, Bahareh Badrian, Steven E. Mutsaers
Disease Markers.2019; 2019: 1. CrossRef
Combination of DNA ploidy analysis and miR-21 or miR-24 in screening malignant pleural effusion
Chongmei Liu, Liuyan Huang, Xuechun Zhang, Juan Yang
Interactive CardioVascular and Thoracic Surgery.2018; 26(3): 376. CrossRef
Microarray expression profile and analysis of circular RNA regulatory network in malignant pleural effusion
Yakun Wen, Yong Wang, Zhenchuan Xing, Zongjian Liu, Ziliang Hou
Cell Cycle.2018; 17(24): 2819. CrossRef
Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis
Mei Feng, Jing Zhu, Liqun Liang, Ni Zeng, Yanqiu Wu, Chun Wan, Yongchun Shen, Fuqiang Wen
International Journal of Clinical Oncology.2017; 22(2): 283. CrossRef
miR-134: A Human Cancer Suppressor?
Jing-Yu Pan, Feng Zhang, Cheng-Cao Sun, Shu-Jun Li, Guang Li, Feng-Yun Gong, Tao Bo, Jing He, Rui-Xi Hua, Wei-Dong Hu, Zhan-Peng Yuan, Xin Wang, Qi-Qiang He, De-Jia Li
Molecular Therapy - Nucleic Acids.2017; 6: 140. CrossRef
Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review)
Jingyu Wang, Yuan Li, Meiman Ding, Honghe Zhang, Xiaoming Xu, Jinlong Tang
International Journal of Oncology.2017; 50(2): 345. CrossRef
MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway
Yuguang Zhao, Dong Pang, Cui Wang, Shijiang Zhong, Shuang Wang
Tumor Biology.2016; 37(8): 11485. CrossRef
MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features
Ruma Dey Ghosh, Sangeeta Ghuwalewala, Pijush Das, Sapan Mandloi, Sk Kayum Alam, Jayanta Chakraborty, Sajal Sarkar, Saikat Chakrabarti, Chinmoy Kumar Panda, Susanta Roychoudhury
Scientific Reports.2016;[Epub] CrossRef
Cell‐free microRNAs in blood and other body fluids, as cancer biomarkers
Blanca Ortiz‐Quintero
Cell Proliferation.2016; 49(3): 281. CrossRef
Clinical relevance of circulating cell-free microRNAs in ovarian cancer
Koji Nakamura, Kenjiro Sawada, Akihiko Yoshimura, Yasuto Kinose, Erika Nakatsuka, Tadashi Kimura
Molecular Cancer.2016;[Epub] CrossRef
MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma
Ling Chen, Guangming Kong, Chuantao Zhang, Hongyan Dong, Cuicui Yang, Guanhua Song, Chengye Guo, Lin Wang, Hongsheng Yu
Oncotarget.2016; 7(15): 20041. CrossRef
Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics
Ningning Yang, Nsikak R. Ekanem, Clement A. Sakyi, Sidhartha D. Ray
Advanced Drug Delivery Reviews.2015; 81: 62. CrossRef
Reduced expression of microRNA-134 correlates with malignancy and poor prognosis in human glioma
Jianfeng Zhong, Bing Li
Journal of Clinical Neuroscience.2015; 22(3): 583. CrossRef
2015 update on the diagnosis and management of neoplastic pericardial disease
Chiara Lestuzzi, Massimiliano Berretta, Witold Tomkowski
Expert Review of Cardiovascular Therapy.2015; 13(4): 377. CrossRef
Extracellular microRNAs in bronchoalveolar lavage samples from patients with lung diseases as predictors for lung cancer
Grit Rehbein, Bernd Schmidt, Michael Fleischhacker
Clinica Chimica Acta.2015; 450: 78. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion

Cancer Res Treat. 2014;46(2):178-185. Published online April 15, 2014

DOI: https://doi.org/10.4143/crt.2014.46.2.178

XML Download

Figure

Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion

Fig. 1 Comparison of miR-134 (A), miR-185 (B), miR-22 (C), and carcinoembryonic antigen (CEA) (D) expression levels in benign pleural effusion (BPE) and lung adenocarcinoma-associated malignant pleural effusion (LA-MPE) samples. Statistical significance was determined by the Mann-Whitney U test.

Fig. 2 Receiver operating characteristic (ROC) curve analysis. The ROC plots for miR-134 (A), miR-185 (B), miR-22 (C), carcinoembryonic antigen (CEA) (D), a combination of three miRNAs (E), and a combination of three miRNAs plus CEA (F) were used to differentiate lung adenocarcinoma-associated malignant pleural effusion from benign pleural effusion. AUC, area under the receiver operating characteristic curve; CI, confidence interval.

Fig. 1

Fig. 2

Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion

	No. of patients (n=87)

	BPE	LA-MPE
No. of cases	42	45
Median age (range, yr)	61 (22-92)	68 (33-92)
Gender
Male	29	23
Female	13	22
Diagnosis of BPE
Tuberculosis	20
Pneumonia	17
Transudate	5
Metastatic sites of LA
M1a^a)		18
M1b^b)		27

Tumor marker	Cut-off	Sensitivity (%)	Specificity (%)	AUC (95% CI)
miR-134	16.99	80.0	57.1	0.721 (0.614-0.812)
miR-185	0.092	77.8	90.5	0.882 (0.795-0.941)
miR-22	0.051	68.9	85.7	0.832 (0.736-0.903)
CEA	7.6	78.4	97.5	0.898 (0.808-0.955)
miR-134, miR-185, and miR-22	0.490	73.3	97.6	0.893 (0.808-0.949)
miR-134, miR-185, miR-22, and CEA	0.268	91.9	92.5	0.942 (0.864-0.982)

Table 1 Characteristics of the study populations

BPE, benign pleural effusion; LA-MPE, lung adenocarcinoma-associated malignant pleural effusion; LA, lung adenocarcinoma.

M1a, separate tumor nodule(s) in a contralateral lobe, a tumor with pleural nodules, or malignant pleural (or pericardial) effusion,

M1b, distant metastasis.

Table 2 Sensitivity, specificity, and areas under the curves for miR-134, miR-185, miR-22, CEA, and combinations of these markers, in lung adenocarcinoma-associated malignant pleural effusion samples

CEA, carcinoembryonic antigen; AUC, area under the curve; CI, confidence interval.